Affordable Access

Publisher Website

Difficulties with the implemented xpert MTB/RIF for determining diagnosis of pulmonary and extrapulmonary tuberculosis in adults and children.

  • Mertaniasih, Ni Made1, 2
  • Soedarsono,3
  • Kusmiati, Tutik3
  • Koendhori, Eko Budi1
  • Kusumaningrum, Deby1
  • Koesprijani,4
  • Sulistyowati, Titiek4
  • Nuha, Zakiyathun2
  • Chanifah, Hatif5
  • 1 Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya 60131, Indonesia. , (Indonesia)
  • 2 Laboratory of Tuberculosis, Institute of Tropical Disease, Universitas Airlangga, Surabaya 60115, Indonesia. , (Indonesia)
  • 3 Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60131, Indonesia. , (Indonesia)
  • 4 Public Health Laboratory of Surabaya, Surabaya 60286, Indonesia. , (Indonesia)
  • 5 Department of Pulmonology and Respiratory Medicine, Dr. Soetomo Hospital, Surabaya, Indonesia. , (Indonesia)
Published Article
Journal of clinical tuberculosis and other mycobacterial diseases
Publication Date
May 01, 2020
DOI: 10.1016/j.jctube.2020.100159
PMID: 32258438


Handling of PTB and EPTB patients with adequate standard detection of MTBC and anti-TB drug sensitivity using accurate and rapid methods could provide good TB management and clinical treatment outcomes. The Xpert MTB/RIF assay is an automated, cartridge-based NAAT that can simultaneously detect MTBC and RIF resistance within 2 h. The aim of this study was to evaluate the implementation of Xpert for determining diagnosis of PTB and EPTB in adults and children. A descriptive study was performed using e-TB Manager data from the MDR-TB Clinic at Dr. Soetomo Academic Hospital. Suspected TB cases were from the areas of East Java Province from January 2016 to December 2018. Xpert assay was conducted using standardized criteria for clinically suspected TB, and MTBC-positive results with RR were examined by the culture method using MGIT 960 BACTEC System. A total of 1181 (1181/3009, 39.25%) sputum samples from suspected new MDR-PTB cases tested positive for MTBC with 3.02% RR. Among 3893 sputum samples from previously treated probable MDR-PTB cases tested using Xpert, 1936 (49.73%) were MTBC positive with 13.20% RR. Among 59 new suspected MDR-PTB cases tested using MGIT 960 BACTEC System, 55 tested positive for MTBC, although all RR strains were highly sensitive to amikacin (100%), kanamycin (95%), and ofloxacin (89%). A total of 49 children with suspected PTB were tested using Xpert, revealing low positivity (12%) for MTBC, with all RR strains being rifampicin sensitive (RS). Of the 86 suspected EPTB cases tested using Xpert, very few were MTBC-positive (26%), with 91% RS. This study revealed that in adults and children with PTB and EPTB, the Xpert assay achieved a low positivity detection rate for MTBC in samples from new or previously treated cases, and this could be the result of many factors. © 2020 The Authors. Published by Elsevier Ltd.

Report this publication


Seen <100 times